Literature DB >> 28205423

The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study.

Eri Kato1, Tetsuji Sawada1, Koichiro Tahara1, Haeru Hayashi1, Mayu Tago1, Hiroaki Mori1, Jinju Nishino2, Toshihiro Matsui3, Shigeto Tohma2.   

Abstract

AIM: To determine whether the age at onset of rheumatoid arthritis (RA) has increased in Japan using a nationwide database (National Database of Rheumatic Diseases by iR-net in Japan, NinJa).
METHOD: We analyzed the data of RA patients who had been diagnosed with early RA (disease duration < 2 years) and newly registered in 2003, 2008 or 2013.
RESULTS: The numbers of patients who developed RA in 2002-2003, 2007-2008, and 2012-2013 were 536, 812 and 1864, respectively. The mean age at RA onset increased significantly from 55.8 years in 2002-2003 and 57.0 years in 2007-2008 to 59.9 years in 2012-2013. The peak age shifted from the 50-59 years age group in 2002-2003 to the 60-69 years age group in 2012-2013. There was no apparent difference in the age at RA onset between male and female RA patients. Notably, in the period 2002-2003, the prevalence of RA was markedly higher in the age group of 50-59 years, which included the first 'baby boomers', than in the age groups of 30-39 and 40-49 years, even with consideration of the variations in the age composition of the general population.
CONCLUSIONS: We have demonstrated that the age at RA onset in Japan has increased significantly over the last decade. This can be attributed to Japan's aging population. In addition, the high prevalence of RA among the first baby boomers suggests that environmental factors might also have contributed to the increase in age at RA onset in Japan.
© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  age at onset; epidemiology; rheumatoid arthritis

Mesh:

Year:  2017        PMID: 28205423     DOI: 10.1111/1756-185X.12998

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  18 in total

Review 1.  Rheumatology practice in Japan: challenges and opportunities.

Authors:  Kenji Oku; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2019-03-19       Impact factor: 2.631

2.  Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan.

Authors:  Masateru Okazaki; Hisanori Kobayashi; Hirohito Shimizu; Yutaka Ishii; Tsutomu Yajima; Masayoshi Kanbori
Journal:  Rheumatol Ther       Date:  2018-03-02

3.  Potential Cancer Risk in Patients with Rheumatoid Arthritis: A Longitudinal Korean Population-Based Analysis.

Authors:  Hyo Geun Choi; Ho Suk Kang; Hyun Lim; Joo-Hee Kim; Ji Hee Kim; Seong-Jin Cho; Eun Sook Nam; Kyueng-Whan Min; Ha Young Park; Nan Young Kim; Mi Jung Kwon
Journal:  J Pers Med       Date:  2022-06-13

4.  Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.

Authors:  Keiko Ogawa; Yoshihiro Kozuka; Hitomi Uno; Kosuke Utsumi; Osamu Noyori; Rumiko Hosoki
Journal:  Clin Drug Investig       Date:  2021-06-10       Impact factor: 2.859

5.  Methotrexate-associated Lymphoproliferative Disorder of the Stomach Presumed to Be Mucosa-associated Lymphoid Tissue Lymphoma.

Authors:  Sho Ishigaki; Tatsuhiro Masaoka; Hisako Kameyama; Miho Kawaida; Kaori Kameyama; Takehiko Mori; Takanori Kanai
Journal:  Intern Med       Date:  2018-11-15       Impact factor: 1.271

6.  Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.

Authors:  Kosuke Ebina; Motomu Hashimoto; Wataru Yamamoto; Toru Hirano; Ryota Hara; Masaki Katayama; Akira Onishi; Koji Nagai; Yonsu Son; Hideki Amuro; Keiichi Yamamoto; Yuichi Maeda; Koichi Murata; Sadao Jinno; Tohru Takeuchi; Makoto Hirao; Atsushi Kumanogoh; Hideki Yoshikawa
Journal:  PLoS One       Date:  2019-05-08       Impact factor: 3.240

7.  Relationship between rheumatoid arthritis and locomotive syndrome: validation of the 25-question Geriatric Locomotive Function Scale in patients with rheumatoid arthritis.

Authors:  Yasumori Sobue; Toshihisa Kojima; Koji Funahashi; Nobuyuki Okui; Masanori Mizuno; Nobunori Takahashi; Shuji Asai; Nobuyuki Asai; Takuya Matsumoto; Tsuyoshi Nishiume; Mochihito Suzuki; Naoki Ishiguro
Journal:  Nagoya J Med Sci       Date:  2019-08       Impact factor: 1.131

8.  Impact of COVID-19 pandemic on outpatient appointments of rheumatic patients in a non-outbreak area of China.

Authors:  Tianhua Xie; Dong Wang; Xia Wang; Qingrui Yang; Hongsheng Sun; Ruihong Liu; Ming Li
Journal:  Wien Klin Wochenschr       Date:  2021-06-18       Impact factor: 1.704

9.  Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.

Authors:  Kunihiro Ichinose; Toshimasa Shimizu; Masataka Umeda; Shoichi Fukui; Ayako Nishino; Tomohiro Koga; Shin-Ya Kawashiri; Naoki Iwamoto; Mami Tamai; Hideki Nakamura; Shuntaro Sato; Tomoki Origuchi; Atsushi Kawakami
Journal:  J Immunol Res       Date:  2018-08-14       Impact factor: 4.818

Review 10.  Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome.

Authors:  Steven Dudics; David Langan; Rakeshchandra R Meka; Shivaprasad H Venkatesha; Brian M Berman; Chun-Tao Che; Kamal D Moudgil
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.